Shuttle Pharma signs $1.45M IR consulting deal

Shuttle Pharmaceuticals Holdings, Inc. entered into a material consulting agreement with IR Agency LLC on September 15, 2025.

Rhea-AI Filing Summary

Shuttle Pharmaceuticals Holdings, Inc. entered into a material consulting agreement with IR Agency LLC on September 15, 2025. IR Agency will provide marketing and advertising services to communicate information about the company to the financial community, including creating company profiles, distributing media, and building a digital community around the company.

As consideration for these services, the company paid IR Agency $1,450,000 for a two‑month term. The full consulting agreement is referenced as an exhibit to the report.

Insights

Equity & corporate governance analyst

Shuttle Pharma commits $1,450,000 to a short-term investor marketing campaign.

Shuttle Pharmaceuticals Holdings, Inc. has signed a two‑month consulting agreement with IR Agency LLC for marketing and advertising services focused on the financial community. The services include creating company profiles, media distribution, and building a digital community around the company, which are designed to increase awareness among investors.

The company paid IR Agency a fee of $1,450,000 for this two‑month engagement, representing a defined cash outflow for promotional activity rather than operations or R&D. The agreement is identified as a material definitive agreement, indicating the board and management view the size or nature of this commitment as important to stakeholders.

Future disclosures in company filings may provide more detail on whether similar marketing arrangements continue beyond this two‑month term or whether this is a one‑time initiative.

8-K Event Classification

2 items: 1.01, 9.01

2 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What agreement did Shuttle Pharmaceuticals (SHPH) enter into on September 15, 2025?

Shuttle Pharmaceuticals Holdings, Inc. entered into a consulting agreement with IR Agency LLC for marketing and advertising services aimed at the financial community.

How much is Shuttle Pharmaceuticals paying IR Agency under this consulting agreement?

Shuttle Pharmaceuticals paid IR Agency LLC a fee of $1,450,000 as consideration for performing the agreed marketing and advertising services.

What services will IR Agency provide to Shuttle Pharmaceuticals (SHPH)?

IR Agency will provide marketing and advertising services, including creating company profiles, distributing media, and building a digital community related to Shuttle Pharmaceuticals.

What is the term of the consulting agreement between Shuttle Pharmaceuticals and IR Agency?

The consulting agreement between Shuttle Pharmaceuticals and IR Agency has a two‑month term.

Where can investors find the full text of Shuttle Pharmaceuticals’ consulting agreement with IR Agency?

The full consulting agreement is filed as Exhibit 10.1 to the report and is incorporated by reference.

Who signed the Shuttle Pharmaceuticals 8-K reporting the IR Agency agreement?

The report was signed on behalf of Shuttle Pharmaceuticals Holdings, Inc. by Christopher Cooper, the Interim Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/22/2025 - 05:00 PM Learn about SEC filing dates

false 0001757499 0001757499 2025-09-15 2025-09-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 15, 2025

SHUTTLE PHARMACEUTICALS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41488		82-5089826
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

401 Professional Drive, Suite 260

Gaithersburg, MD 20879

(Address of principal executive offices) (Zip Code)

(240) 430-4212

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock $0.00001 per share		SHPH		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

On September 15, 2025, Shuttle Pharmaceuticals Holdings, Inc.(the “Company”), entered into a consulting agreement with IR Agency LLC (the “IR Agency”). Pursuant to the consulting agreement, IR Agency agreed to provide marketing and advertising services to communicate information about the Company to the financial community (the “Services”), including, but not limited to, creating company profiles, media distribution and building a digital community with respect to the Company. As consideration for the performance of the Services, the Company paid IR Agency $1,450,000. The term of the consulting agreement will be two months.

The foregoing description of the consulting agreement is qualified by reference to the full text of the consulting agreement, which is filed as Exhibit 10.1 hereto and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
10.1		Consulting Agreement, dated September 15, 2025, between Shuttle Pharmaceuticals Holdings, Inc. and IR Agency LLC.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
Dated: September 22, 2025
	By:	/s/ Christopher Cooper
	Name:	Christopher Cooper
	Title:	Interim Chief Executive Officer

3